Long-term survival can be achieved following salvage radiation for nodal recurrence of endometrial cancer. However, central and distant recurrences remain a challenge. Chemotherapy prior to radiation was associated with an increased rate of central recurrences and reduced survival, while the use of concurrent chemotherapy was associated with higher rates of survival.
Our results suggest that p16 overexpression can act as a marker for PFS and LRC in EBV-positive nasopharyngeal carcinoma patients. This interesting finding raises the possibility of further stratifying more aggressive phenotypes within EBV-positive tumors. Therefore, molecular testing of p16 expression may complement EBV status to provide more detailed and comprehensive guidance in determining the prognosis and predicting treatment outcomes for patients diagnosed with nasopharyngeal carcinoma.
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
Disparities exist in PT utilization compared with IMRT by age, race, and SES and merit further investigation.
(P016) The Cell Cycle Inhibitor P21 Regulates Langerhans Cell Radiation Resistance and PromotesT Regulatory Cell Induction Upon Exposure to Radiotherapy
Future analyses will seek to elaborate the functional implications of LCs and IR-sensitive DC IR-exposure as it relates to the priming and development of graft-versus-host disease (GVHD) and local antitumor immunity following radiation therapy.
When corrected for comorbid conditions in this patient cohort, CaP patients with less than 10% %LN+ have almost 14 years before their disease becomes incurable. Progressively larger %LN+ yields smaller windows of such time. Above 50% LN+, the inflection point is only about 4 years. While better therapies for pN+ CaP must be defined, this patient cadre is not homogenous and should be stratified by %LN+ in future clinical trials.
(S033) Predictive Capacity of Three Comorbidity Indices in Estimating Survival Endpoints in Women With Early-Stage Endometrial Carcinoma
While all three comorbidity indices correlated significantly with OS in women with early-stage EC, AACCI was the only independent predictor of OS and should be considered for evaluating comorbidity in future endometrial cancer patients.
(S053) Nodal Surveillance With Diffusion-Weighted MRI After Definitive (Chemo) Radiotherapy for HPV-Predominant Squamous Cell Cancers of the Oropharynx and Unknown Primary
Early surveillance imaging with diffusion-weighted MRI at 6–8 weeks following definitive treatment with radiotherapy is feasible and may be predictive of early nodal failure. Further validation in a prospective cohort is warranted.
(P034) Proton Therapy (PT) Large-Volume Re-Irradiation for Recurrent Glioma: Overall Survival (OS) and Toxicity Outcomes
Large-volume PT re-irradiation for recurrent glioma is safe and associated with promising OS outcomes, particularly in the setting of bevacizumab-refractory tumors.
(P050) Yttrium-90 Radioembolization for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases in KRAS Wild-type and Mutant Patients
90Y radioembolization is an effective treatment for CRCLMs in extending local control for liver-dominant metastatic disease. However, KRAS-mutant tumors may be more radioresistant to treatment.
Prognostic factors that were significantly associated with survival on both UV and MV analyses were used to construct a valid scoring system that can be used to predict survival of NSCLC patients. The score can be used for trial stratification or for choosing patients specifically for high-risk trials. Optimally, this score will be helpful when counseling patients and designing future trials.